WOS

Permanent URI for this collectionhttps://hdl.handle.net/11443/932

Browse

Author: search.filters.author.Demir, Selim

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Incidence, risk factors and severity of retinopathy of prematurity in Turkey (TR-ROP study): a prospective, multicentre study in 69 neonatal intensive care units
    (BMJ PUBLISHING GROUP, 2018-01-01) Bas, Ahmet Yagmur; Demirel, Nihal; Koc, Esin; Isik, Dilek Ulubas; Hirfanoglu, Ibrahim Murat; Tunc, Turan; Sari, Fatma Nur; Karatekin, Guner; Koklu, Esad; Altunhan, Huseyin; Turgut, Hatice; Narter, Fatma; Tarakci, Nuriye; Tekgunduz, Kadir Serafettin; Ozkiraz, Servet; Aydemir, Cumhur; Ozdemir, Ahmet; Cetinkaya, Bilin; Kazanci, Ebru; Tastekin, Ayhan; Calkavur, Sebnem; Ozyurt, Banu Mutlu; Demirelli, Yasar; Asker, Huseyin Selim; Mutlu, Birgul; Uygur, Ozgun; Ozkan, Hilal; Armangil, Didem; Ozlu, Ferda; Mert, Mustafa Kurthan; Ergin, Hacer; Ozcan, Beyza; Bas, Evrim Kiray; Okulu, Emel; Acunas, Betul; Celik, Ulker; Uslu, Sait Ilker; Mutlu, Mehmet; Demir, Nihat; Eroglu, Funda; Gokmen, Zeynel; Beken, Serdar; Bayraktar, Bilge Tanyeri; Hakan, Nilay; Kucuktasci, Kazim; Orman, Aysen; Comert, Serdar; Ertugrul, Sabahattin; Ustun, Nuran; Sahin, Ozlem; Terek, Demet; Kale, Yusuf; Konak, Murat; Yurttutan, Sadik; Aydemir, Ozge; Zenciroglu, Aysegul; Sarici, Dilek; Guzoglu, Nilufer; Hamilcikan, Sahin; Gursoy, Tugba; Tuzun, Funda; Ors, Rahmi; Arslan, Selda; Akdag, Arzu; Memisoglu, Asli; Yasa, Beril; Hekimoglu, Berna; Turan, Ozden; Aylanc, Hakan; Takci, Sahin; Celik, Tolga; Sahin, Suzan; Kilic, Ilknur; Kara, Caner; Tunay, Zuhal Ozen; Celik, Gokhan; Gozen, Ibrahim; Satirtav, Gunhal; Polat, Nihat; Oral, Ayse Yesim; Tokgoz, Mine; Keles, Sadullah; Bilgin, Burak; Ugurbas, Silay Canturk; Karaca, Cagatay; Keskek, Nedime Sahinoglu; Ekinci, Dilbade Yildiz; Balci, Ozlem; Altan, Emir Volkan; Bakbak, Sevda; Ceylan, Nihan Aksu; Kimyon, Sabit; Alyamac, Gunay; Ture, Gamze; Yildiz, Meral; Calis, Feyza; Sizmaz, Selcuk; Sukgen, Emine; Cetin, Ebru Nevin; Ozcimen, Muammer; Demir, Semra Tiryaki; Atila, Huban; Ozal, Altan; Tufaner, Gokhan; Yucel, Ozlem Eski; Kola, Mehmet; Seven, Erbil; Ozdek, Sengul; Durukan, Ali Hakan; Kal, Ali; Celebi, Ali Riza Cenk; Koytak, Ibrahim Arif; Alacamli, Goksu; Esme, Arif; Catak, Onur; Perente, Irfan; Sahin, Alparslan; Akcakaya, Aylin Ardagil; Kiray, Gulunay; Nalcaci, Serhat; Aksoy, Umit; Bakbak, Berker; Comez, Aysegul; Gursoy, Huseyin; Kabatas, Emrah Utku; Petricli, Ikbal Seza; Yumusak, Mehmet Erhan; Kirgiz, Ahmet; Uludag, Gunay; Yaman, Aylin; Dadaci, Zeynep; Karatas, Ali; Celiker, Hande; Cebeci, Zafer; Esenulku, Mahmut Cenap; Akkoyun, Imren; Ersan, Ismail; Demir, Selim; Kadayifcilar, Sibel; Unsal, Ayse Ipek Akyuz; Hocaoglu, Mumin; Grp, T. R.-R.O.P. Study
    Background To evaluate the prevalence, risk factors and treatment of retinopathy of prematurity (ROP) in Turkey and to establish screening criteria for this condition. Methods A prospective cohort study (TR-ROP) was performed between 1 April 2016 and 30 April 2017 in 69 neonatal intensive care units (NICUs). Infants with a birth weight (BW)=1500 g or gestational age (GA)<= 32 weeks and those with a BW> 1500 g or GA> 32 weeks with an unstable clinical course were included in the study. Predictors for the development of ROP were determined by logistic regression analyses. Results The TR-ROP study included 6115 infants: 4964 (81\%) with a GA <= 32 weeks and 1151 (19\%) with a GA>32 weeks. Overall, 27\% had any stage of ROP and 6.7\% had severe ROP. A lower BW, smaller GA, total days on oxygen, late-onset sepsis, frequency of red blood cell transfusions and relative weight gain were identified as independent risk factors for severe ROP in infants with a BW=1500 g. Of all infants, 414 needed treatment and 395 (95.4\%) of the treated infants had a BW <= 1500 g. Sixty-six (16\%) of the treated infants did not fulfil the Early Treatment for Retinopathy of Prematurity requirements for treatment. Conclusions Screening of infants with a GA <= 34 weeks or a BW<1700 g appears to be appropriate in Turkey. Monitoring standards of neonatal care and conducting quality improvement projects across the country are recommended to improve neonatal outcomes in Turkish NICUs.
  • Thumbnail Image
    Item
    Ischemia-modified albumin and the IMA/albumin ratio in the dignosis and staging of hemorrhagic shock: A randomized controlled experimental study
    (TURKISH ASSOC TRAUMA EMERGENCY SURGERY, 2020-01-01) Turedi, Suleyman; Sahin, Aynur; Akca, Metehan; Demir, Selim; Kose, Gokcen Derya Reis; Cekic, Arif Burak; Yildirim, Mehmet; Yulug, Ersin; Mentese, Ahmet; Turkmen, Suha; Acar, Sami
    BACKGROUND: To determine the value of ischemia-modified albumin (IMA) and IMA/albumin ratio (IMAR) in the diagnosis and staging of hemorrhagic shock (HS). METHODS: A pressure-targeted HS model was established in this study. The control and shock groups were monitored for 30 min and 60 min to simulate varying durations of exposure to HS. All subjects underwent invasive arterial monitoring during the experiment and were further divided into mild and severe shock groups based on decreases in mean arterial pressure (MAP). Biochemical and histologic comparisons were performed between the groups. RESULTS: Our results revealed higher IMA, IMAR, lactate, total oxidant status (TOS) and oxidative stress index (OSI) levels in both the 30- and 60-min shock groups compared to the control group. Concerning MAP-based shock staging, IMA, IMAR, lactate, TOS and OSI levels in the 30-min and 60-min mild and severe shock groups were higher than those of the controls. However, there was no significant difference between the mild and severe shock groups. A significant correlation was determined between all the biomarkers evaluated and HS-induced damage in various organs. This correlation was highest in lactate and IMAR levels. CONCLUSION: IMA and IMAR levels may be used in the early diagnosis of HS and also have the potential for use in determining the severity of HS. IMA and IMAR measurement may also be considered as an alternative or in addition to lactate measurement in the diagnosis of HS.
  • Thumbnail Image
    Item
    A Comparison of the Effects of Grayanotoxin-Containing Honey (Mad Honey), Normal Honey, and Propolis on Fracture Healing
    (KARGER, 2018-01-01) Sahin, Aynur; Turkmen, Suha; Guzel, Nizamettin; Mentese, Ahmet; Turedi, Suleyman; Karahan, Suleyman Caner; Yulug, Esin; Demir, Selim; Aynaci, Osman; Deger, Orhan; Gunduz, Abdulkadir
    Objectives: Delayed healing and non-union of fractures have a significant effect upon patient morbidity. Studies have therefore largely concentrated on accelerating fracture healing. This study was intended to compare the effect of ``mad honey{''} and propolis on fracture healing using radiological and histopathological analysis. Subjects and Methods: Femur fracture was surgically performed on 48 rats, followed by fixation. Animals were then divided into 8 groups: 2 control groups (15-and 30-day) and 6 treatment groups (15-and 30-day normal honey, 15-and 30-day ``mad honey,{''} and 15-and 30-day propolis). Rats were sacrificed at the end of these periods, and radiological and histological examinations were performed. Results: Radiological healing in the propolis group after 15-day therapy was statistically better than in the control (p = 0.004) and normal honey (p = 0.006) groups. After 30-day therapy, healing in the propolis group (p = 0.005) and grayanotoxin-containing ``mad honey{''} group (p = 0.007) were significantly better than in the control group. Histologically, there was a statistically significant difference between the 15-day propolis group and the other groups (control, honey, mad honey: p = 0.003, p = 0.003, and p = 0.002, respectively). We also found a statistically significant difference when the 30-day propolis group (p = 0.005) and `` mad honey{''} group (p = 0.007) were compared to the control group. Conclusions: This study shows that grayanotoxin-containing `` mad honey{''} and propolis can accelerate fracture healing. (C) 2018 The Author(s) Published by S. Karger AG, Basel.